The efficacy and safety of tocilizumab in patients with neuromyelitis optica

The efficacy and safety of tocilizumab in patients with neuromyelitis optica - The efficacy and safety of tocilizumab in patients with neuromyelitis optica

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022201

Enrollment

Registered

2016-05-04

Start date

2016-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromyelitis optica

Interventions

Tocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of neuromyelitis optica(NMO),as defined by 2006 criteria published in NEUROLOGY vol.66 or NMO seropositive spectrum disorder.All patients must be anti-aquaporin4 antibody seropositive. They also have resistance or cannot continue nomal treatment because of side effects.

Exclusion criteria

Exclusion criteria: 1)Patients with severe infection such at tuberculosis, pneumocystis carinii pneumonia, nontuberculosis mycobacterial infection, hepatitis B,hepatitis C, or chronic active FB virus infection. 2)Patients with a history of hypersensitivity to this drug. 3)Patients with interstitial pneumoniris. 4)Patients with lymphopenia.(lymphocyte number <500/mm3) 5)Pregnant women or patients with possible pregnancy.

Design outcomes

Primary

Measure	Time frame
Relapse tate up to years EDSS up to 2 years	—

Countries

Japan

Contacts

Public ContactChizuko Hamada

Shimane University Hospital Department of Neurology

okuzihc@med.shimane-u.ac.jp0853-20-2198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026